Bexxar, Iodine I 131 Tositumomab, Effective in Long-Term Follow-Up of Non-Hodgkin's Lymphoma

    July 2007 in “ Cancer biology & therapy ”
    Studysummary This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →